People treated for hepatitis C have unexpectedly high rate of liver cancer recurrence
Portugal's roll-out of HCV therapy with DAAs achieves impressive results
DAAs achieve excellent outcomes in real-world settings
High incidence of HCV reinfection among HIV-positive MSM in Western Europe
Sofosbuvir/velpatasvir cures HCV in 95% of people with HCV and HIV co-infection
Six weeks of sofosbuvir/ledipasvir is enough to cure acute hepatitis C in HIV-negative people
Tenofovir alafenamide works well against hepatitis B with less effect on bones and kidneys
Low-cost generic hepatitis C drugs match branded products in viral response
Shifting hepatitis C treatment to primary care providers could expand availability
